Bio Pharma Dive
OCTOBER 4, 2024
An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under regulatory scrutiny.
Pharmaceutical Technology
OCTOBER 4, 2024
Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
OCTOBER 4, 2024
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
Pharmaceutical Technology
OCTOBER 4, 2024
WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
OCTOBER 4, 2024
The gene editing company is selling to DRI Healthcare Trust future license fees that are owed to it under an agreement with Vertex last year.
Pharmaceutical Technology
OCTOBER 4, 2024
It is common for sponsors to switch digital platforms between clinical trial phases, but sponsors can achieve much by using the same one.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
OCTOBER 4, 2024
Two years after the FDA placed partial clinical hold, Avidity can resume research of del-desiran as a treatment for myotonic dystrophy type 1.
Fierce Pharma
OCTOBER 4, 2024
After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.
Pharmaceutical Technology
OCTOBER 4, 2024
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical director.
pharmaphorum
OCTOBER 4, 2024
Bristol Myers Squibb (BMS) has been granted approval by the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).
Pharmaceutical Technology
OCTOBER 4, 2024
Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.
Fierce Pharma
OCTOBER 4, 2024
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo. In 2022, Enjaymo became the first and only therapy specifically approved by the FDA for treating patients with the uncommon blood disorder cold agglutinin disease.
Pharmaceutical Technology
OCTOBER 4, 2024
Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.
pharmaphorum
OCTOBER 4, 2024
FDA declares an end to tirzepatide shortage, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
OCTOBER 4, 2024
National Resilience’s subsidiary Resilience Government Services has received around $17.5m in funding for expanding critical medicine components manufacturing.
XTalks
OCTOBER 4, 2024
The push to increase diversity in clinical trials has gained momentum, but true progress requires more than regulatory mandates. It involves building trust, fostering authentic relationships and amplifying the voices of those most impacted by health inequities. While the pharmaceutical industry has made strides in improving patient diversity in clinical trials, a recent webinar moderated by Kevin Aniskovich, CEO of Jumo Health, underscored that much work remains to ensure trials are truly inclus
Pharmaceutical Technology
OCTOBER 4, 2024
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).
XTalks
OCTOBER 4, 2024
The US Food and Drug Administration (FDA) has approved Exact Sciences’ Cologuard Plus, a next-generation, non-invasive colorectal cancer (CRC) screening test for adults aged 45 and older at average risk for CRC. Cologuard Plus builds on the original Cologuard test by incorporating enhanced biomarkers and laboratory processes, offering a more effective way to detect CRC at earlier, treatable stages and identify advanced precancers.
BioPharma Reporter
OCTOBER 4, 2024
Rebekah's father passed on his passion for science and problem solving to her and much her of childhood was spent doing fun hands-on activities from taking apart household mechanics to building rockets.
Outsourcing Pharma
OCTOBER 4, 2024
Patient recruitment is a critical and often challenging aspect of clinical trials, particularly for biopharmaceutical companies seeking to accelerate drug development.
Drug Channels
OCTOBER 4, 2024
Today’s guest post comes from Timothy Nielsen, Vice President of Customer Success at AssistRx. Timothy discusses the affordability and patient journey challenges of specialty-lite products for patients, manufacturers, and health care providers. He explains how AssistRx's Advanced Access Anywhere (AAA) solution streamlines processes for specialty-lite products and facilitates enrollment via a digital hub.
Outsourcing Pharma
OCTOBER 4, 2024
Outsourcing Pharma sat down ahead of CPHI with Dr Andreas Raabe, CEO of Adragos Pharma, to explore the evolving world of pharmaceutical outsourcing.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Intouch Solutions
OCTOBER 4, 2024
The 16th annual PM360 Trailblazer Awards was a night to remember for EVERSANA INTOUCH! Our team was honored at Gotham Hall in New York City, taking home five awards across several categories: Gold: Marketing Team of the Year – Corcept Therapeutics Gold: Consumer Website/Online Initiative – Eczema Skin Gallery, Sanofi, Regeneron Pharmaceuticals, Inc.
Pharmaceutical Commerce
OCTOBER 4, 2024
The latest news for pharma industry insiders.
WCG Clinical
OCTOBER 4, 2024
Rheumatoid arthritis (RA) is the most common of the inflammatory arthropathies, affecting nearly 1% of the population with a female preponderance. Onset is typically between 45 and 65 years of age. While the etiology RA is unknown, it is thought to be largely autoimmune. Lack of treatment results in rapid progression of disease with significant joint destruction, pain, and loss of function.
XTalks
OCTOBER 4, 2024
In this episode, Ayesha spoke with James E. Brown, DVM, co-founder, President and CEO of DURECT. DURECT is pioneering a therapeutic strategy by leveraging the potential of epigenetic modulation to alter the trajectory of severe and life-threatening conditions like acute organ injury and cancer. The company is specifically focused on the development of an epigenetic modulator, larsucosterol (DUR-928) for the treatment of alcohol-associated hepatitis (AH).
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Commerce
OCTOBER 4, 2024
Getting a handle on level of compliance-readiness for the Drug Supply Chain Security Act deadline—now just weeks away.
XTalks
OCTOBER 4, 2024
October 6 is World Cerebral Palsy Day , an annual global event that helps raise awareness about cerebral palsy, and celebrate the lives and accomplishments of individuals living with the condition. Many will wear green to celebrate World Cerebral Palsy Day 2024. The theme of this year’s World Cerebral Palsy Day is “Uniquely CP,” which encourages individuals with the condition, their family members and supporters to share stories about their achievements and passions, highlighting how cerebral pa
Pharmaceutical Commerce
OCTOBER 4, 2024
Headlining our October issue of Pharmaceutical Commerce is a look inside an emerging key component of cold chain transport and management—ensuring the safety and control of novel injectable drugs through to their "last mile.
pharmaphorum
OCTOBER 4, 2024
LSX 2024 features an insightful interview with Hakim Yadi and Luba Greenwood, discussing innovation, healthcare, and more. Learn from their expertise and perspectives in this exclusive discussion.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
360 
Let's personalize your content